Medtronic is paying $235 million to purchase RF Surgical Systems, which has a technology that's intended to make it easier to detect and prevent surgical items such as sponges, gauze or towels from being left behind in a patient.
Orthopedics player Smith & Nephew is rounding out its presence in emerging markets with the acquisition of the trauma and orthopedics business as well as a manufacturing company of the DeOst Group. The Russian company manufactures medical devices and has also served as Smith & Nephew's product distributor in the region since 2009.
Charles River Laboratories has struck a deal to buy Celsis International for $212 million, nabbing its complementary bacterial detection systems for quality-control testing.
AstraZeneca has been working hard lately to get its sales on an upward track, a feat it expects to achieve in the not-too-distant future. In the meantime, though, it's looking to plug the holes, and it struck a divestment deal Thursday to help do just that--and streamline its focus, too.
Preclinical CRO Charles River Laboratories is paying $212 million in cash to buy a company focused on quality-control testing, expanding its presence in the market for bacterial detection services.
CRO BioClinica inked a deal to acquire MediciGroup, a patient recruitment and retention outfit that uses technology to keep subjects engaged in trials and minimize dropouts.
Despite inking its deal to buy Ireland's Vidara Therapeutics at the height of the U.S. tax inversion backlash, former Illinois company Horizon Pharma didn't back down. It closed its acquisition right before new, stricter tax inversion rules took hold--and now, as it embarks on a hostile pursuit of California's Depomed, it's reaping the benefits in more ways than one.
Chinese medical device player Mindray Medical was down 7% in early trading on the news that it would acquire the remaining stake of orthopedics player Wuhan Dragonbio Surgical Implant Co. Mindray first gained a controlling stake in Dragonbio for $35.5 million in 2012. Investors may be taking the deal as a sign that a June take-private offer is now off the table. The deal is slated to close this month.
Drugmakers can't be excited about the wave of consolidation going through the health insurance business. After all, pharma knows firsthand how mergers can put the screws to prices; just think of Express Scripts and its Medco buyout.
Last week, analysts pointed out that Horizon Pharma had plenty of potential buyouts to choose from, unlike bigger companies looking for bigger deals. Now, the $5 billion market-cap company has zeroed in on a target: Depomed, the pain drug specialist.